Clinical Trials Browser

INDUSTRY × Leukemia × Alemtuzumab × Clear all

NCT00328198 2014-03-13

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Phase 2 Completed

86 enrolled 15 charts

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell